NT-proBNP Predicts Ventricular Arrhythmias in Non-Compaction

Why It Matters

Identifying high‑risk LVNC patients enables targeted monitoring and preventive therapies, potentially reducing sudden cardiac death rates.

Key Takeaways

• Elevated NT‑proBNP linked to higher arrhythmia risk
• Study included 120 non‑compaction patients
• Threshold 300 pg/mL identified optimal cutoff
• Risk independent of ejection fraction
• Early biomarker could guide monitoring

Pulse Analysis

Left ventricular non‑compaction (LVNC) is a genetic cardiomyopathy characterized by deep trabeculations and impaired myocardial contraction. While heart failure dominates the clinical picture, ventricular arrhythmias are a leading cause of sudden death. NT‑proBNP, a peptide released in response to myocardial stretch, has long been used to gauge heart failure severity, but its role in arrhythmia prediction has remained underexplored. Recent advances in high‑sensitivity assays now allow clinicians to detect subtle biomarker shifts that may herald electrical instability.

In a multicenter cohort of 120 LVNC patients, investigators measured baseline NT‑proBNP and followed participants for a median of 24 months. Those with levels above 300 pg/mL experienced a three‑fold increase in documented ventricular tachycardia or fibrillation compared with lower‑level counterparts. Importantly, the predictive power persisted after controlling for left ventricular ejection fraction, scar burden on MRI, and medication use, indicating that NT‑proBNP captures a distinct pathophysiological signal—likely reflecting heightened wall stress and neuro‑hormonal activation that predisposes to arrhythmogenesis.

The findings have immediate clinical relevance. Incorporating NT‑proBNP testing into routine LVNC assessments could refine risk stratification, guiding decisions about implantable cardioverter‑defibrillator placement or intensified anti‑arrhythmic therapy. Moreover, pharmaceutical firms developing novel heart‑failure agents may leverage NT‑proBNP as a surrogate endpoint in LVNC trials, accelerating drug development pipelines. As real‑world data accumulate, the biomarker may become a cornerstone of personalized care for a population that currently lacks robust prognostic tools.